Free shipping on all orders over $ 500

Monalizumab

Cat. No. M21501
Monalizumab  Structure
Synonym:

IPH2201

Size Price Availability Quantity
1mg USD 490  USD490 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Monalizumab is a first-in-class immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab can be used in the study of head and neck squamous cell carcinoma (HNSCC).

Chemical Information
CAS Number 1228763-95-8
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Jeongjae Lee, et al. J Cancer Res Clin Oncol. Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines

[2] Roy S Herbst, et al. J Clin Oncol. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer

[3] Linda Borst, et al. Clin Cancer Res. The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment

[4] Thorbald van Hall, et al. J Immunother Cancer. Monalizumab: inhibiting the novel immune checkpoint NKG2A

[5] Pascale Andr, et al. Cell. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

Related Checkpoint Products
CBP501 Affinity Peptide

CBP501 Affinity Peptide is a Chk kinase inhibitor that can abrogate G2 arrest induced by DNA-damaging agents.

Chktide

Chktide is a substrate for CHK1 and CHK2.

Zn-DPA-maytansinoid conjugate 1

Zn-DPA-maytansinoid conjugate 1 is a small molecule-based maytansinoid conjugate targeting immune checkpoint.

CHK1-IN-7

CHK1-IN-7 is a potent human CHK1 inhibitor.

Chk2-IN-1 

Chk2-IN-1 (compound 1) is a potent and selective inhibitor of checkpoint kinase 2 (Chk2), with IC50s of 13.5 nM and 220.4 nM for Chk2 and Chk1, respectively. Chk2-IN-1 can elicit a strong ataxia telangiectasia mutated (ATM)-dependent Chk2-mediated radioprotection effect.

  Catalog
Abmole Inhibitor Catalog




Keywords: Monalizumab , IPH2201 supplier, Checkpoint, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.